Literature DB >> 7880797

Pilot study on the effect of topical adrenergic medications on human Tenon's capsule fibroblasts in tissue culture.

I A Cunliffe1, C A McIntyre, R C Rees, I G Rennie.   

Abstract

Recent publications have suggested that the long term use of topical antiglaucoma medications may be detrimental to the outcome of trabeculectomy. In order to investigate this further, the effect of several adrenergic agents and a preservative on the proliferation and viability of human Tenon's capsule fibroblasts in tissue culture were examined. The following compounds were tested: adrenaline (Eppy 1% and pure adrenaline base 1%, Smith & Nephew Pharmaceuticals Ltd); dipivefrine hydrochloride (Propine 0.1% and pure dipivefrine hydrochloride 0.1% Allergan Ltd and Allergan Pharmaceuticals (Ireland) Ltd); benzalkonium chloride (pure benzalkonium chloride 0.01%, Sigma Chemical Company Ltd); the two adrenaline based preparations were also tested in the presence of an antioxidant. None of the tested compounds stimulated the proliferation of fibroblasts. The commercial products tested, their pure compounds, and the preservative all inhibited proliferation and had toxic effects on the cells. In the presence of antioxidant, commercial Eppy and pure adrenaline base appeared to have less effect on proliferation and toxicity. These findings are discussed with reference to the outcome of trabeculectomy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7880797      PMCID: PMC505024          DOI: 10.1136/bjo.79.1.70

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  32 in total

1.  Pemphigoid related to epinephrine treatment.

Authors:  K J Hoffer
Journal:  Am J Ophthalmol       Date:  1977-04       Impact factor: 5.258

Review 2.  Adverse external ocular effects of topical ophthalmic medications.

Authors:  F M Wilson
Journal:  Surv Ophthalmol       Date:  1979 Sep-Oct       Impact factor: 6.048

3.  Benign mucous membrane pemphigoid. 1. Secretion of mucus and tears.

Authors:  E B Kristensen; M S Norn
Journal:  Acta Ophthalmol (Copenh)       Date:  1974

4.  Antiglaucoma drug effects on corneal epithelium. A comparative study in tissue culture.

Authors:  L Krejci; R Harrison
Journal:  Arch Ophthalmol       Date:  1970-12

Review 5.  Primary surgery for primary open angle glaucoma--justified or not?

Authors:  R A Hitchings
Journal:  Br J Ophthalmol       Date:  1993-07       Impact factor: 4.638

6.  Pharmacology of ocular drugs: 2. Epinephrine.

Authors:  S M Podos
Journal:  Ophthalmology       Date:  1980-07       Impact factor: 12.079

7.  The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study.

Authors:  R R Pfister; N Burstein
Journal:  Invest Ophthalmol       Date:  1976-04

8.  Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma.

Authors:  A N Kohn; A P Moss; N A Hargett; R Ritch; H Smith; S M Podos
Journal:  Am J Ophthalmol       Date:  1979-02       Impact factor: 5.258

9.  Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas.

Authors:  N L Burstein
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-03       Impact factor: 4.799

10.  External ocular toxicity of dipivalyl epinephrine.

Authors:  J Theodore; H M Leibowitz
Journal:  Am J Ophthalmol       Date:  1979-12       Impact factor: 5.258

View more
  2 in total

1.  Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid.

Authors:  R L Gross
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Isoproterenol induces an increase in muscle fiber size by the proliferation of Pax7-positive cells and in a mTOR-independent mechanism.

Authors:  Úrsula Maria C Bastos; Ivone de Andrade Rosa; John D Teixeira; Graciele Gonçalves; Manoel L Costa; Luis Eduardo M Quintas; Claudia Mermelstein
Journal:  Cell Biol Int       Date:  2019-06-05       Impact factor: 3.612

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.